Difference between revisions of "Large granular lymphocytic leukemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 50%"|Study !style="width: 50%"|Evidence |-")
m
Line 1: Line 1:
−
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
 
−
 
−
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
 
−
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 11: Line 7:
  
 
=Guidelines=
 
=Guidelines=
 +
=="How I Treat"==
 +
*'''2011:''' Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011 Mar 10;117(10):2764-74. [http://bloodjournal.hematologylibrary.org/content/117/10/2764.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062292/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21190991 PubMed]
 
==[https://www.nccn.org/ NCCN]==
 
==[https://www.nccn.org/ NCCN]==
 
*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas] - contains information about T-cell Large Granular Lymphocytic Leukemia
 
*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas] - contains information about T-cell Large Granular Lymphocytic Leukemia
Line 40: Line 38:
 
# '''Retrospective:''' Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15;98(2):483-5. [http://bloodjournal.hematologylibrary.org/content/98/2/483.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=11435321 PubMed]
 
# '''Retrospective:''' Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15;98(2):483-5. [http://bloodjournal.hematologylibrary.org/content/98/2/483.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=11435321 PubMed]
 
# '''Retrospective:''' Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, Schleinitz N, Tournilhac O, Roussel M, Fest T, Lamy T. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010 Sep;95(9):1534-41. [http://www.haematologica.org/content/95/9/1534.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930955/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20378561 PubMed] content property of [http://hemonc.org HemOnc.org]
 
# '''Retrospective:''' Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, Schleinitz N, Tournilhac O, Roussel M, Fest T, Lamy T. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010 Sep;95(9):1534-41. [http://www.haematologica.org/content/95/9/1534.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930955/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20378561 PubMed] content property of [http://hemonc.org HemOnc.org]
−
# '''Review:''' Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011 Mar 10;117(10):2764-74. [http://bloodjournal.hematologylibrary.org/content/117/10/2764.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062292/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21190991 PubMed]
 
 
# '''Retrospective:''' Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014 May;28(5):1134-6. Epub 2013 Nov 27. [https://www.nature.com/leu/journal/v28/n5/full/leu2013359a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017255/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24280867 PubMed]
 
# '''Retrospective:''' Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014 May;28(5):1134-6. Epub 2013 Nov 27. [https://www.nature.com/leu/journal/v28/n5/full/leu2013359a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017255/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24280867 PubMed]
  
Line 64: Line 61:
  
 
'''28-day cycles'''
 
'''28-day cycles'''
−
 
+
====Subsequent treatment====
−
''Patients with PR continue up to one year; patients with CR continue for one month past documented CR. Non-responders were transitioned to [[#Cyclophosphamide_.26_Prednisone|cyclophosphamide & prednisone]].''
+
*Patients with PR: continue up to one year
 +
*Patients with CR: continue for one month past documented CR
 +
*Non-responders were transitioned to [[#Cyclophosphamide_.26_Prednisone|cyclophosphamide & prednisone]]
  
 
===References===
 
===References===
−
# '''Review:''' Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011 Mar 10;117(10):2764-74. [http://bloodjournal.hematologylibrary.org/content/117/10/2764.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062292/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21190991 PubMed]
+
# '''ECOG E5998:''' Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. [https://www.nature.com/leu/journal/vaop/naam/pdf/leu2014298a.pdf link to original article]  '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25306898 PubMed]
−
# Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. [https://www.nature.com/leu/journal/vaop/naam/pdf/leu2014298a.pdf link to original article]  '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25306898 PubMed]
 
  
 
=Relapsed or refractory=
 
=Relapsed or refractory=
Line 78: Line 76:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
−
 
 
===Regimen {{#subobject:c27546|Variant=1}}===
 
===Regimen {{#subobject:c27546|Variant=1}}===
 
{| class="wikitable" style="width: 100%; text-align:center;"  
 
{| class="wikitable" style="width: 100%; text-align:center;"  
−
!Study
+
!style="width: 33%"|Study
−
![[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
|'''ORR'''
+
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
|-
 
|-
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ Loughran et al. 2014 (ECOG E5998)]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ Loughran et al. 2014 (ECOG E5998)]
 
|style="background-color:#91cf61"|Phase II
 
|style="background-color:#91cf61"|Phase II
−
|64% (95% CI, 35-87)
+
|ORR: 64% (95% CI, 35-87)
 
|-
 
|-
 
|}
 
|}
−
''Preceded by treatment failure on [[#Methotrexate_.26_Prednisone|methotrexate & prednisone]].''
+
''Note: Patients with PR continue up to one year; patients with CR continue for one month past documented CR.''
 +
====Preceding treatment====
 +
*[[#Methotrexate_.26_Prednisone|Methotrexate & prednisone]], with treatment failure
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once per day
 
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once per day
 
*[[Prednisone (Sterapred)]] 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described)
 
*[[Prednisone (Sterapred)]] 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described)
  
−
'''28-day cycles'''
+
'''28-day cycles (see note)'''
−
 
 
−
''Patients with PR continue up to one year; patients with CR continue for one month past documented CR.''
 
  
 
===References===
 
===References===
−
# Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. [https://www.nature.com/leu/journal/vaop/naam/pdf/leu2014298a.pdf link to original article]  '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25306898 PubMed]
+
# '''ECOG E5998:''' Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. [https://www.nature.com/leu/journal/vaop/naam/pdf/leu2014298a.pdf link to original article]  '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377298/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25306898 PubMed]
  
 
[[Category:Large granular lymphocytic leukemia regimens]]
 
[[Category:Large granular lymphocytic leukemia regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:T-cell lymphomas]]
 
[[Category:T-cell lymphomas]]

Revision as of 02:07, 23 August 2018

3 regimens on this page
3 variants on this page


Guidelines

"How I Treat"

NCCN

Initial therapy

Cyclophosphamide monotherapy

back to top

Regimen

Study Evidence
Bareau et al. 2010 Retrospective

These are retrospective series, of which Bareau et al. 2010 is representative. The most common dose reported is 100 mg PO once per day; some authors mentions co-administration of steroids but details are not supplied.

Chemotherapy

Lamy et al. 2011 recommends that patients who are responding are continued on treatment for 6 to 12 months; patients who do not respond within 4 months of therapy are discontinued

References

  1. Retrospective: Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001 Jul 15;98(2):483-5. link to original article PubMed
  2. Retrospective: Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, Schleinitz N, Tournilhac O, Roussel M, Fest T, Lamy T. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010 Sep;95(9):1534-41. link to original article link to PMC article PubMed content property of HemOnc.org
  3. Retrospective: Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, Roussel M, Fest T, Awwad A, Baab K, Semenzato G, Houot R, Loughran TP Jr, Lamy T. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014 May;28(5):1134-6. Epub 2013 Nov 27. link to original article link to PMC article PubMed

Methotrexate & Prednisone

back to top

Regimen

Study Evidence
Loughran et al. 2014 (ECOG E5998) Phase II

Chemotherapy

  • Methotrexate (MTX) 10 mg/m2 PO "in divided doses" once per week
    • Details not described in ECOG E5998; Lamy et al. 2011 divides the 10 mg/m2 methotrexate dose into 5 mg/m2 in the morning and 5 mg/m2 in the evening
  • Prednisone (Sterapred) 1 mg/kg PO once per day for 30 days, then tapered off over 24 days (details not described)

28-day cycles

Subsequent treatment

  • Patients with PR: continue up to one year
  • Patients with CR: continue for one month past documented CR
  • Non-responders were transitioned to cyclophosphamide & prednisone

References

  1. ECOG E5998: Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. link to original article contains verified protocol link to PMC article PubMed

Relapsed or refractory

Cyclophosphamide & Prednisone

back to top

Regimen

Study Evidence Efficacy
Loughran et al. 2014 (ECOG E5998) Phase II ORR: 64% (95% CI, 35-87)

Note: Patients with PR continue up to one year; patients with CR continue for one month past documented CR.

Preceding treatment

Chemotherapy

28-day cycles (see note)

References

  1. ECOG E5998: Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94. Epub 2014 Sep 13. link to original article contains verified protocol link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Large_granular_lymphocytic_leukemia&oldid=30647"